A/Prof Himisha Beltran

ProMis Team Leader Profile

Himisha-BeltranA/Prof Himisha Beltran, MD

A/Prof of Medicine, Division of Medical Oncology,

Weill Cornell Medical College

Full research profile



After receiving her medical degree from New York Medical College in 2004, A/Prof Beltran completed her residency training in Internal Medicine at the University of Pennsylvania and fellowship in Hematology and Medical Oncology at Weill Cornell Medical College. She joined faculty at Weill Cornell Medical College in 2011 as Assistant Professor in Medical Oncology and is Director of the Precision Medicine Clinic of the Institute for Precision Medicine of NewYork Presbyterian-Weill Cornell since its inception in February 2013. She is actively involved in both laboratory-based and clinical research, and she serves as the liaison for several bench-to-bedside translational research efforts at Weill Cornell and with external collaborators.

A/Prof Beltran’s clinical specialty is in caring for patients with genitourinary malignancies. She has been particularly focused on utilising next generation genomic sequencing and integrative molecular analysis of advanced metastatic prostate tumours towards developing precision cancer care and biomarker driven clinical trials. As Director of the Precision Medicine Clinic, A/Prof Beltran developed an Institutional Review Board approved protocol to perform sequencing and follow patients prospectively while on systemic therapies. She has worked with a multidisciplinary team to develop effective precision medicine biopsy protocols to enhance tissue collection and quality for sequencing and integrate data with clinical follow-up including response to targeted therapies and survival endpoints.

A/Prof Beltran has a strong track record of clinical translation and has used the science she generated in her laboratory to develop novel biomarkers and a multi-institutional Phase 2 trial of a targeted therapy for patients with neuroendocrine prostate cancer. Her research has also brought increased attention to identifying and targeting androgen receptor (AR) negative prostate cancer as a late stage phenotype in prostate cancer.

A/Prof Beltran’s research is currently funded by the United States National Institute of Health, United States Department of Defense, Prostate Cancer Foundation, Starr Cancer Foundation, and Damon Runyon Cancer Research Foundation.